Jordan vs Paraguay: Average cost of multi drug-resistant tuberculosis treatment
Jordan
5,124 constant 2022 US$
in 2024
Paraguay
11,664 constant 2022 US$
in 2024
Jordan rank
8th
Paraguay rank
5th
Average cost of multi drug-resistant tuberculosis treatment over time
- Jordan
- Paraguay
How they compare
Paraguay currently reports 11,664 constant 2022 US$ against 5,124 constant 2022 US$ in Jordan, a difference of 6,540 constant 2022 US$.
That makes Paraguay's figure about 2.3 times Jordan's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Paraguay ahead.
Jordan ranks 8th and Paraguay ranks 5th of 92 countries.
Across the 2 decades both report, Jordan averaged higher in 1 and Paraguay in 1.
Head to head by decade
| Decade | Jordan | Paraguay | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 12,250 constant 2022 US$ | 2,559 constant 2022 US$ | 9,691 constant 2022 US$ | Jordan |
| 2020s | 4,181 constant 2022 US$ | 4,347 constant 2022 US$ | 166.25 constant 2022 US$ | Paraguay |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Jordan or Paraguay?
- Paraguay, at 11,664 constant 2022 US$ against 5,124 constant 2022 US$ in Jordan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Jordan and Paraguay?
- 6,540 constant 2022 US$, with Paraguay ahead.
- How many years of comparable data are there for Jordan and Paraguay?
- 7 years are reported by both, from 2017 to 2024.
- How do Jordan and Paraguay rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Jordan ranks 8th and Paraguay ranks 5th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.